Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab ##### Up next ![ZIEA Unveils World's First AI Desktop Calendar Designed to Reclaim Your Focus in an Age of Distraction](https://i0.wp.com/mma.prnasia.com/media2/2843624/image1.jpg?resize=200%2C110&ssl=1 "ZIEA Unveils World's First AI Desktop Calendar Designed to Reclaim Your Focus in an Age of Distraction") [](https://thailandbusinessnews.net/press-release/ziea-unveils-worlds-first-ai-desktop-calendar-designed-to-reclaim-your-focus-in-an-age-of-distraction/) ###### [ZIEA Unveils World's First AI Desktop Calendar Designed to Reclaim Your Focus in an Age of Distraction](https://thailandbusinessnews.net/press-release/ziea-unveils-worlds-first-ai-desktop-calendar-designed-to-reclaim-your-focus-in-an-age-of-distraction/) Published on 12 December 2025 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) HONG KONG, Dec. 12, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study will compare cadonilimab plus chemotherapy against chemotherapy with or without nivolumab as first-line treatment for HER2-negative, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma. This is the second international registrational study for cadonilimab, following the ongoing trial in immunotherapy-resistant hepatocellular carcinoma. COMPASSION-37 represents a pivotal advancement in cadonilimab’s global development and a concrete step in Akeso’s worldwide strategy, reinforcing its leadership in next-generation immuno-oncology. The company remains committed to its dual-track approach of proprietary development and strategic collaboration, leveraging global resources to accelerate cadonilimab’s international availability and expand accessible treatment options for patients worldwide. Chemotherapy with or without PD-1 inhibitors, such as nivolumab, represents the international standard of care for advanced gastric cancer. However, the disease exhibits significant heterogeneity. While PD-1 treatment in combination with chemotherapy remains an effective treatment in many gastric cancer patients with high PD-L1 expression (CPS >5), its efficacy is markedly limited in gastric cancer patients with low PD-L1 expression (CPS <5) or negative PD-L1 expression (CPS <1). These low and negative PD-L1 patients constitute well more than half of the total gastric cancer patient population. In 2024, the FDA narrowed the indication for all approved PD-1 inhibitors in the first-line treatment of advanced gastric cancer, restricting their use to PD-L1-positive patients. Authoritative guidelines, including those from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), also prioritize recommending nivolumab-based regimens for patients with PD-L1 CPS ≥5. This underscores that treating advanced gastric cancer in PD-L1 low-expressing and negative patients has become a globally recognized clinical challenge. In 2024, based on the COMPASSION-15 study results, cadonilimab in combination with chemotherapy was approved in China for the first-line treatment of gastric cancer, demonstrating benefit across all patient populations, including both PD-L1 positive and negative subgroups. COMPASSION-15 is the only global Phase III clinical study in first-line advanced gastric cancer to have demonstrated survival benefit across all patient populations, irrespective of PD-L1 expression status. In this trial, patients with low PD-L1 expression and those who were PD-L1-negative accounted for as high as 49.8% and 23% of the enrolled population, respectively, significantly exceeding proportions observed in historical studies of its kind. The robust representation of low and negative PD-L1 patients in the study and the effective treatment of these patients validates cadonilimab’s broad-spectrum antitumor efficacy beyond PD-L1 dependency in gastric cancer. Long-term follow-up data showed that cadonilimab plus chemotherapy significantly reduced the risk of death by 39% in the overall population compared to the control group (OS HR 0.61), regardless of PD-L1 status. In the PD-L1 CPS ≥5 subgroup, the reduction in mortality risk reached 51% (OS HR 0.49). Importantly, even among patients with low PD-L1 expression (CPS <5), a statistically significant 24% reduction in mortality risk was maintained (OS HR 0.76). These results were presented as an oral report at ESMO 2025. Earlier interim analysis data from the COMPASSION-15 study had been released as a prominent oral presentation at AACR 2024, with the full manuscript subsequently published in the Nature Medicine. These results highlight cadonilimab’s potential to elevate the current standard of tumor immunotherapy and address clinical challenges unmet by single-target agents. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. About Akeso Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 26 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit and follow us on [Linkedin](https://www.linkedin.com/company/akeso-bio/posts/?feedView=all). [Source link ](https://www.prnasia.com/story/archive/4845248_CN45248_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/111-inc-announces-first-quarter-2025-unaudited-financial-results/) ## 111, Inc. Announces First Quarter 2025 Unaudited Financial Results Maintained Quarterly Operational Profitability Operating Expenses as a Percentage of Revenues Decreased… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - June 19, 2025 [](https://thailandbusinessnews.net/press-release/minaris-advanced-therapies-launches-as-the-leading-global-partner-dedicated-to-cell-therapy-development-manufacturing-and-testing/) ## Minaris Advanced Therapies launches as the leading global partner dedicated to cell therapy development, manufacturing, and testing New company unveiled at the annual ISCT conference in New Orleans combines… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - May 7, 2025 [](https://thailandbusinessnews.net/press-release/a-journey-from-serving-masters-to-serving-the-people/) ## A journey from serving masters to serving the people BEIJING, March 24, 2025 /PRNewswire/ — A news report from Beijing Review: Padma… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - March 24, 2025 ##### Most Read - [![Manulife appoints Sarah Chapman as Global Chief Marketing & Customer Experience Officer, joining Executive Leadership Team](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/manulife-appoints-sarah-chapman-as-global-chief-marketing-customer-experience-officer-joining-executive-leadership-team/ "Manulife appoints Sarah Chapman as Global Chief Marketing & Customer Experience Officer, joining Executive Leadership Team") [Manulife appoints Sarah Chapman as Global Chief Marketing & Customer Experience Officer, joining Executive Leadership Team](https://thailandbusinessnews.net/press-release/manulife-appoints-sarah-chapman-as-global-chief-marketing-customer-experience-officer-joining-executive-leadership-team/ "Manulife appoints Sarah Chapman as Global Chief Marketing & Customer Experience Officer, joining Executive Leadership Team") - [![ReThink HK 2026 Opens at HKCEC, Bringing Business, Government and NGOs Together to Accelerate Climate Action](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/rethink-hk-2026-opens-at-hkcec-bringing-business-government-and-ngos-together-to-accelerate-climate-action/ "ReThink HK 2026 Opens at HKCEC, Bringing Business, Government and NGOs Together to Accelerate Climate Action") [ReThink HK 2026 Opens at HKCEC, Bringing Business, Government and NGOs Together to Accelerate Climate Action](https://thailandbusinessnews.net/press-release/rethink-hk-2026-opens-at-hkcec-bringing-business-government-and-ngos-together-to-accelerate-climate-action/ "ReThink HK 2026 Opens at HKCEC, Bringing Business, Government and NGOs Together to Accelerate Climate Action") - [![Fashion Summit (HK) 2026 "Code the Fashion Forward" at the Hong Kong Palace Museum: Global Fashion Leaders, Innovators, and Local Design Talents Gather, Sharing Insights to Co-create a Green and Smart New Chapter in Fashion](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/fashion-summit-hk-2026-code-the-fashion-forward-at-the-hong-kong-palace-museum-global-fashion-leaders-innovators-and-local-design-talents-gather-sharing-insights-to-co-create-a-green/ "Fashion Summit (HK) 2026 "Code the Fashion Forward" at the Hong Kong Palace Museum: Global Fashion Leaders, Innovators, and Local Design Talents Gather, Sharing Insights to Co-create a Green and Smart New Chapter in Fashion") [Fashion Summit (HK) 2026 "Code the Fashion Forward" at the Hong Kong Palace Museum: Global Fashion Leaders, Innovators, and Local Design Talents Gather, Sharing Insights to Co-create a Green and Smart New Chapter in Fashion](https://thailandbusinessnews.net/press-release/fashion-summit-hk-2026-code-the-fashion-forward-at-the-hong-kong-palace-museum-global-fashion-leaders-innovators-and-local-design-talents-gather-sharing-insights-to-co-create-a-green/ "Fashion Summit (HK) 2026 "Code the Fashion Forward" at the Hong Kong Palace Museum: Global Fashion Leaders, Innovators, and Local Design Talents Gather, Sharing Insights to Co-create a Green and Smart New Chapter in Fashion") - [![Midea Unveils VitaBreeze: An AC Beyond Cooling and Heating](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/midea-unveils-vitabreeze-an-ac-beyond-cooling-and-heating/ "Midea Unveils VitaBreeze: An AC Beyond Cooling and Heating") [Midea Unveils VitaBreeze: An AC Beyond Cooling and Heating](https://thailandbusinessnews.net/press-release/midea-unveils-vitabreeze-an-ac-beyond-cooling-and-heating/ "Midea Unveils VitaBreeze: An AC Beyond Cooling and Heating") - [![Alpha Ladder WealthX Among Asia's First to Bring xStocks US Tokenised Equities to Institutional and Accredited Investors](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/alpha-ladder-wealthx-among-asias-first-to-bring-xstocks-us-tokenised-equities-to-institutional-and-accredited-investors/ "Alpha Ladder WealthX Among Asia's First to Bring xStocks US Tokenised Equities to Institutional and Accredited Investors") [Alpha Ladder WealthX Among Asia's First to Bring xStocks US Tokenised Equities to Institutional and Accredited Investors](https://thailandbusinessnews.net/press-release/alpha-ladder-wealthx-among-asias-first-to-bring-xstocks-us-tokenised-equities-to-institutional-and-accredited-investors/ "Alpha Ladder WealthX Among Asia's First to Bring xStocks US Tokenised Equities to Institutional and Accredited Investors") - [![SJourney Enters a New Chapter with Arsenale's 33% Strategic Investment](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/sjourney-enters-a-new-chapter-with-arsenales-33-strategic-investment/ "SJourney Enters a New Chapter with Arsenale's 33% Strategic Investment") [SJourney Enters a New Chapter with Arsenale's 33% Strategic Investment](https://thailandbusinessnews.net/press-release/sjourney-enters-a-new-chapter-with-arsenales-33-strategic-investment/ "SJourney Enters a New Chapter with Arsenale's 33% Strategic Investment") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/qivika-to-launch-smart-scope-on-kickstarter-bringing-a-professional-long-range-experience-to-day-and-night-exploration/) ![QIVIKA to Launch Smart Scope on Kickstarter, Bringing a Professional Long-Range Experience to Day-and-Night Exploration](https://i0.wp.com/mmx.prnasia.com/media/MS1986483/20260911084649EDT_image_1.jpg?resize=260%2C140&ssl=1 "QIVIKA to Launch Smart Scope on Kickstarter, Bringing a Professional Long-Range Experience to Day-and-Night Exploration") ## QIVIKA to Launch Smart Scope on Kickstarter, Bringing a Professional Long-Range Experience to Day-and-Night Exploration BERLIN and NEW YORK, Sept. 12, 2026 /PRNewswire/ — QIVIKA, a consumer… [](https://thailandbusinessnews.net/press-release/the-generation-essential-groups-receipt-of-nyse-letter-regarding-class-a-ordinary-shares-trading-price/) ## The Generation Essential Group's Receipt of NYSE Letter Regarding Class A Ordinary Shares Trading Price NEW YORK and LONDON, Sept. 12, 2026 /PRNewswire/ — The Generation Essentials… [](https://thailandbusinessnews.net/press-release/quantinuum-to-participate-in-the-piper-sandler-5th-annual-growth-frontiers-conference/) ## Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference BROOMFIELD, Colo., Sept. 12, 2026 /PRNewswire/ — Quantinuum Inc. (Nasdaq: QNT)… [](https://thailandbusinessnews.net/press-release/cgtn-how-brics-creates-new-opportunities-for-global-south-development/) ## CGTN: How BRICS creates new opportunities for Global South development CGTN published an article examining how China’s four global initiatives are…